Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Sanofi Introduces IMOVAX-Polio as Replacement for ShanIPV Injectable Vaccine
French pharmaceutical giant Sanofi has received approval for IMOVAX-Polio, offering a viable alternative to the existing ShanIPV injectable vaccine in India
- By PharmaNews Live Desk
- New Delhi
- Apr 08, 2024
French pharmaceutical giant Sanofi has received approval for IMOVAX-Polio in India. Media reports reveal that Sanofi’s latest alternative, IMOVAX-Polio, will take the place of the current Inactivated Polio Vaccine (IPV) ShanIP in India.
IMOVAX-Polio, an alternative IPV vaccine with a history of over 40 years of global usage, is set to ensure continuity in India’s efforts to remain polio-free, reassured a Sanofi India spokesperson.
Addressing concerns about vaccine availability, the spokesperson emphasized Sanofi’s commitment to public health in India, promising no shortages of IPV vaccines with the introduction of IMOVAX-Polio.
In response to emerging trends, Sanofi Healthcare India Pvt Ltd (SHIPL) announced plans to discontinue ShanIPV by the end of 2023, aligning with its evolving strategy and portfolio adjustments.
Launched in 2015, ShanIPV, a trivalent inactivated injectable vaccine, was an integral part of India’s immunization programme, administered in two stages at six weeks and 14 weeks of age.
Sanofi and Serum Institute of India stand as key suppliers of IPV vaccines in the country, with Sanofi aiming to introduce new drugs, enhance localization, and expand market reach through collaborations with domestic pharmaceutical companies, according to recent reports by media outlets.